Health
Clover Biopharmaceuticals Announces Positive Preclinical Data and Updates on Phase 1 Study for its Adjuvanted S-Trimer COVID-19 Vaccine Candidate – Press Release – Digital Journal
Joshua Liang, Chief Executive Officer of Clover Biopharmaceuticals, said, “We are excited to share these important preclinical results showing that our S-Trimer COVID-19 vaccine candidate induces immune protection against SARS-CoV-2, and we are also pleased w…
CHENGDU, China–(Business Wire)–Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on discovering and developing transformative biologic therapies and vaccines, today announced positive preclinical data demonstrating that its protein-based COVID-19 S-Trimer vaccine candidate in combination with adjuvants from either GSK (London Stock Exchange: GSK) or Dynavax (Nasdaq: DVAX) induces a strong immune response and protection against SARS-CoV-2 in animal models. The man…
-
General11 hours agoARIA Awards 2025 winners: Amyl & The Sniffers and Ninajirachi dominate
-
Noosa News20 hours agoChild, 15, arrested over death of another child, 8, after shocking e-bike crash in Queensland
-
General18 hours agoCrowe toasts talkback titan for platforming ‘voiceless’
-
Noosa News18 hours agoDeath of German shepherd Arnie prompts Brisbane community action to protect pets caught up in crime